[{"orgOrder":0,"company":"Galderma","sponsor":"Certara","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"RAR-gamma","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AbobotulinumtoxinA","moa":"Ach release","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable Gel Implant","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Alastin Skincare","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Herbal Extract","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Alastin Skincare","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Herbal Extract","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Topical Solution","sponsorNew":"Galderma \/ Taro Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Taro Pharmaceutical"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach release","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Ipsen"},{"orgOrder":0,"company":"Galderma","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BotulinumtoxinA","moa":"Ach","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BotulinumtoxinA","moa":"ACh","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Termination","leadProduct":"Botulinum toxin type A","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Galderma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","graph1":null,"graph2":null,"graph3":"Galderma","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Galderma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Galderma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
